




## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>5</sup> :</b> A01N 25/02, 25/08, A61F 2/04 A61M 25/01	<b>A1</b>	<b>(11) International Publication Number:</b> WO 94/10838 <b>(43) International Publication Date:</b> 26 May 1994 (26.05.94)
<b>(21) International Application Number:</b> PCT/US93/10893 <b>(22) International Filing Date:</b> 12 November 1993 (12.11.93)  <b>(30) Priority data:</b> 07/975,486 12 November 1992 (12.11.92) US  <b>(71) Applicant:</b> BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM [US/US]; 201 West 7th Street, Austin, TX 78701 (US).  <b>(72) Inventors:</b> RAAD, Issam ; 7615 Del Rey Lane, Houston, TX 77071 (US). SHERERTZ, Robert, J. ; 3417 Jameson Lane, Winston-Salam, NC 27106 (US).  <b>(74) Agent:</b> MAYFIELD, Denise, L.; Arnold, White & Durkee, P.O. Box 4433, Houston, TX 77210 (US).		<b>(81) Designated States:</b> AU, CA, JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> M-EDTA PHARMACEUTICAL PREPARATIONS AND USES THEREOF		
<b>(57) Abstract</b> <p>Disclosed are pharmaceutical compositions of a mixture of minocycline and EDTA (M-EDTA) and methods of using the compositions in maintaining the patency of a catheter port. Methods for inhibiting the formation of polysaccharide-rich glycocalyx (such as the glycocalyx of staphylococcal organisms) are also provided using an M-EDTA solution. A solution including minocycline, EDTA or both, may also be used to pretreat a medical device to prevent adherence of infectious organisms, such as <i>S. epidermidis</i> and <i>S. aureus</i>. The compositions destroy and prevent the formation of polysaccharide-rich glycocalyx. Methods for treating infections of <i>S. epidermidis</i> and <i>S. aureus</i> where glycocalyx formation are provided with an M-EDTA solution. The minocycline and EDTA solutions are included together within a pharmacologically acceptable carrier solution, such as saline.</p> 		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

-1-

DESCRIPTIONM-EDTA PHARMACEUTICAL PREPARATIONS AND USES THEREOF

5

BACKGROUND OF THE INVENTION1. FIELD OF THE INVENTION

10 The present invention relates to indwelling medical articles, such as catheters, which may also be flushed or coated with a microbial-inhibiting pharmaceutical preparation. The invention also relates to pharmaceutical preparations useful in maintaining catheter patency and preventing infection. Methods of  
15 using the pharmaceutical preparation of the invention in the management and maintenance of a vascular catheter are also related to the present disclosure.

2. BACKGROUND OF THE RELATED ART

20

Indwelling medical devices including vascular catheters have become essential in the management of hospitalized or chronically ill patients. Unfortunately, vascular catheters have become the major source for  
25 hospital-acquired sepsis. Hence, the benefit derived from indwelling medical devices such as vascular catheters is often upset by infectious complications. Thrombotic occlusions of the lumen of central venous catheters (CVC) is another complication that will often  
30 lead to the removal of catheters.

The current standard care of catheters includes flushing the lumen of the catheter with heparin. However, heparin has no antimicrobial activity. Thus,  
35 infections, as well as thrombotic occlusion, continue to occur frequently despite the prophylactic use of heparin flushes. Knowledge of the pathogenesis and microbiology

-2-

of central venous catheter-related infections is essential in order to provide effective prevention for this problem. Three essential factors must be considered in controlling for catheter colonization by infectious microbes. The first is controlling the availability of microorganisms that adhere to the inert catheter surface. Such microorganisms typically include staphylococci and candida. The second is controlling the production of a polysaccharide by adherent known as organisms fibrous glycocalyx. Production of the glycocalyx is essential for the adherence and integrity of these organisms. The third is control of the formation of a thrombin sheath by the host, which acts to engulf the catheter. The thrombin sheath provides the microorganisms a sticky substrate for enhanced adherence to the catheter, and thus, continued colonization and infection at the catheter site. The present inventors herein disclose an M-EDTA solution unique in its ability to inhibit all three of these essential conditions, and thus provide effective methods for controlling catheter-related infection and onset thereof.

*Staphylococcus epidermidis* and *S. aureus* account for 75% of CVC related infections. *Candida* species account for another 10% to 15% of such infections. The use of antistaphylococcal antibiotics to prevent these infections has been found to reduce CVC related bacterial infections, but only at the expense of the occurrence of higher rates of fungal (*Candida*) infections. The fibrous glycocalyx material produced by staphylococci and *Candida* helps these organisms adhere and stick to catheter surfaces, thus exacerbating the problem of eliminating these types of infections after they have become established. These microbial biofilm layers are made of a fibrous glycocalyx material primarily polysaccharide in nature. The protective sheath provided by the glycocalyx at the infected site effectively prevents the elimination

-3-

and treatment of these infections. Preparations effective for destroying such a glycocalyx would, therefore, provide a solution for treating established catheter infections, particularly where a glycocalyx is  
5 already formed.

Compositionally distinct glycocalyx material is produced by a variety of different organisms. For example, a mostly protein glycocalyx produced by  
10 *Hymenolepis diminuta* (tapeworm) is reportedly eliminated upon treatment with 0.02 M-EDTA or 3 M KCl<sup>12</sup>. This material, however, is compositionally distinct from the material of the glycocalyx formed by organisms that typically colonize and cause catheter infection. For  
15 example, the glycocalyx of several staphylococcus species comprise primarily polysaccharides with only low to nondeductible levels of protein<sup>13</sup> (Tojo et al. at pg. 716, Table 1). Glycocalyx of microorganisms common to catheter infection are thus compositionally distinct from  
20 the glycocalyx of such organisms as the tapeworm, *Hymenolepis diminuta*. A pharmaceutical preparation effective for reducing or eliminating glycocalyx of infectious microorganisms typically associated with catheter colonization and infection has yet to be  
25 identified.

Infectious microorganisms will typically embed themselves in the protective layer of the glycocalyx, thus providing a shield or hiding place that protects  
30 staphylococci and fungi from the activity of the host's phagocytic cells. An agent or composition that would dissolve or prevent the glycocalyx (biofilm) formation of these clinically important pathogens would thus provide a major breakthrough in the prevention of typical catheter-  
35 related *Staphylococcal* and *Candida* infections.

-4-

There has also been observed to be a correlation between thrombogenesis and infection. Indwelling vascular catheters are typically engulfed by a fibrin sheath that subsequently acts to cover the internal and external surfaces of a catheter. This fibrin sheath provides such organisms as *Staphylococci* and *Candida*, with an enhanced adherence capacity to the catheter surface. Unlike these particular microbes, gram-negative bacilli do not adhere well to fibrin and fibronectin. A composition that halts fibrin formation would thus be particularly useful in halting the colonization of these microbes at indwelling catheter sites.

Intraluminal colonization through a catheter hub also constitutes a prelude to catheter-related infections and septicemias in long-term CVC. The inventors study presented herein of long-term CVC patients (studied by quantitative catheter culture) demonstrates that CVC's with positive cultures as well as matched negative controls evidenced colonization (as quantitated by EM) and biofilm formation of the internal surface at least twice greater than that of external surface with catheters that stayed longer than 10 days in place. This data is from nontunneled, noncuffed percutaneous CVC. For tunneled CVCs (Hickman/Broviac) and ports, internal colonization was even more prominent. The development of an anticoagulant pharmaceutical preparation effective against staphylococci, fungi, and polysaccharide-rich glycoalyx formation, such as that observed during microorganism intraluminal colonization of a catheter hub, would provide a solution to the treatment and elimination of thrombogenesis and the septicemia associated with long-term CVC.

35

EDTA is an anticoagulant used in blood collection, and is also described as having an antibacterial and

-5-

antistaphylococcal effect (alone or in combination)<sup>1-3</sup>. Root<sup>9</sup> described the efficacy of EDTA in vascular catheters as an antibacterial agent as compared to heparin alone and as compared to a vancomycin-heparin preparation *in vitro*. These investigators found EDTA to have some bacteriocidal activity. However, no remedy or suggestion for treatment of how a microbial glycocalyx, such as that observed during *in vivo* catheter-related infection, was observed or described.

10

Glycopeptide antibiotics (vancomycin and teicoplanin) are active against staphylococci *in vitro* and in tissue. Vancomycin is currently the standard antibiotic used in the treatment of *Staphylococcus epidermidis* and resistant *Staphylococcus aureus*. However, these antibiotics are not active against adherent staphylococci embedded in a biofilm layer, such as glycocalyx. In addition, while catheter flushing with such agents may destroy initial strains of staphylococci, such is typically not effective against tolerant and resistant strains of the organism that continue the infection. Flushing with an antibiotic preparation, such as vacomycin, would therefore be of only limited therapeutic value against catheter infection.

25

The ideal prophylactic agent or treatment for catheter maintenance would inhibit or eliminate the formation of polysaccharide-rich glycocalyx of microorganisms and would also inhibit staphylococci and fungi infectious growth.

30

It is an object of the invention to provide both an anti-staphylococcal and antifungal (anti-*Candida*) active agent effective against free-floating as well as adherent organisms embedded in biofilm, as well as to provide an anticoagulant agent and/or method that would prevent or inhibit the formation of polysaccharide-rich fibrous

35

-6-

glycocalyx biofilm layer. Such a pharmaceutical agent would optimally prevent thrombotic occlusion of the catheter lumen and prevent thrombin formation. Additional objects of the invention include providing an agent that could be given intraluminally without a toxicity concern to humans and to provide a method that would kill adherent *Staphylococci* and *Candida*. Such methods would preferably not include the use of pharmaceutical agents typically used to treat non-catheter related infections (such as Vancomycin, Ampho B, or Azoles).

The present invention demonstrates that a mixture of minocycline/disodium EDTA (referred to as M-EDTA) does fulfill all of the listed objects.

#### SUMMARY OF THE INVENTION

The present invention provides a unique and effective pharmaceutical preparation that includes minocycline and EDTA. These mixtures are shown to be effective for maintaining the patency of a medical device, such as a catheter, *in vivo*. As used in the description of the present invention, "patency" is defined as the state of being freely open or patulous, particularly a catheter opening that is unobscured by the formation of a microorganismal polysaccharide-rich fibrous glycocalyx. In a preferred embodiment, minocycline and EDTA are included in the disclosed preparations in pharmacologically effective amounts together in a pharmacologically acceptable carrier solution.

The EDTA of the preparation provides potent glycocalyx inhibiting potential, while the minocycline at high concentrations has a fungicidal effect and a unique ability to penetrate a polysaccharide-rich glycocalyx



-7-

biofilm layer. The combination of minocycline-EDTA thus provides a uniquely effective anticoagulant, anti-microbial, glycocalyx inhibiting, antibacterial and antifungal agent for the prevention of thrombogenesis, microbial adherence and device-related infections.

The inventors demonstrate that minocycline has the surprising activity of penetrating a polysaccharide-rich microbial glycocalyx biofilm layer at least 6-fold more effectively than vancomycin. The inventors also demonstrate that EDTA effectively prevents and dissolves polysaccharide-rich microbial glycocalyx formation at implanted catheter sites *in vivo*.

In still another aspect of the invention, methods for using minocycline as an antimicrobial agent are provided. Minocycline is demonstrated to kill adherent staphylococci (embedded in glycocalyx - Example 4), and to be superior to vancomycin as an antibacterial agent (Table 3) in actual *in vivo* trials.

For use in maintaining catheter patency, the pharmaceutical preparation of the invention may be efficaciously used in conjunction with virtually any device in which a clear path for the flow of biological fluids is necessary. For example, such devices include a central venous catheter, a peripheral intervenous catheter, an arterial catheter, a Swan-Ganz catheter, a hemodialysis catheter, an umbilical catheter, a percutaneous nontunneled silicone catheter, a cuffed tunneled central venous catheter as well as a subcutaneous central venous port.

In a preferred embodiment, a solution of the M-EDTA may be prepared containing a concentration of between about 10 to about 100 mg/ml EDTA (preferably between about 20 to about 60 mg/ml) and between about 0.001 to

-8-

about 100 mg/ml minocycline (preferably between about 2 and about 9 mg/ml). Most preferably, the preparation as a device or catheter flushing solution includes about 30 mg/ml EDTA and about 3 mg/ml minocycline. The

5 minocycline may preferably be prepared as a reconstituted minocycline preparation, such as from a 100 mg vial of minocycline commercially available (Minocin Intravenous, Lederle (Carolina, Puerto Rico). The carrier solution, by way of example, may comprise saline, preferably

10 sterile saline, available from commercial sources.

In another aspect of the invention, a catheter flushing solution is provided. Most preferably, the catheter flushing solution comprises a glycoalkaloid

15 inhibiting concentration of EDTA and minocycline in a pharmaceutically acceptable carrier solution. More specifically, the concentration of EDTA in the flushing preparation is between about 1 to about 100 mg/ml with the concentration of minocycline being between about

20 0.001 to about 100 mg/ml in the preparation. Most preferably, the catheter flushing solution includes about 30 mg/ml EDTA and about 3 mg/ml minocycline.

By way of example, the carrier solution of the

25 flushing preparation is saline, preferably sterile saline. The catheter flushing preparation of the present invention may advantageously be used to inhibit the formation of polysaccharide-rich glycoalkaloid. In this manner, infections characterized by the presence of a

30 polysaccharide-rich glycoalkaloid, such as a glycoalkaloid which is at least 50% polysaccharide by composition, may be effectively treated and/or eliminated.

A "glycoalkaloid inhibiting concentration" is defined

35 for purposes of describing the present invention as a concentration of minocycline, EDTA or a combination thereof effective to degrade, dissolve, or otherwise

-9-

inhibit polysaccharide-rich glycocalyx formation. By way of example, a polysaccharide-rich glycocalyx is characteristic of established staphylococcal infections of *S. aureus* and *S. epidermidis*.

5

Another aspect of the present invention provides a method of preparing a biofilm-resistant device, as well as bio-film resistant devices that are coated with at least one of minocycline or EDTA. Most preferably the device is to be coated with a mixture of minocycline and EDTA. The method in one embodiment comprises coating a device with a coating preparation minocycline and EDTA. While the method may be used to coat virtually any surface where glycocalyx formation is to be desirably inhibited, use of the method in coating a catheter device is particularly envisioned. It is anticipated that the method will provide a device resistant to polysaccharide-rich (at least about 50% polysaccharide) glycocalyx formation, such as that characteristic of Staphylococci. Any of a variety of catheters may be treated or coated according to the described method employing coating techniques well known to those of skill in the art. By way of example, catheters that may be prepared and treated according to the invention include a central venous catheter and a triple lumen catheter.

In a most preferred embodiment, the method for preparing a biofilm-resistant medical device using a pharmaceutical preparation of minocycline and EDTA comprises preparing a solution of at least one of minocycline or sodium EDTA, most preferably in a biocompatible adherent coating carrier solution, and treating the surface of the medical device of interest with the solution for a period of time sufficient to allow the formation of a film of the minocycline, EDTA, or both to the surface of the device. Most preferably,

-10-

the method is to be used in preparing a biofilm-resistant coating on the surface of a catheter.

Alternatively, a coating of the M-EDTA preparation  
5 may be provided at the surface of a device by first  
treating the surface of the device with a surfactant.  
Such surfactants include, by way of example, tridodecyl-  
methyl ammonium chloride (TDMACC). Commercially  
available catheters with such a surfactant already  
10 included on the surface are the Bioguard Cook catheters.  
Accordingly, a device including a surface surfactant may  
be immersed in a solution of minocycline, EDTA or M-EDTA  
for a period of time sufficient to allow the solution to  
permeate the device surface. By way of example, the  
15 present inventors have found that immersion of a device  
in a solution containing about 60 mg minocycline and/or  
about 60 mg EDTA/ml for about 15 minutes at room  
temperature is sufficient to provide a coating of the  
solution to the surface of the device. The device is  
20 preferably air dried and gas sterilized prior to use.

As used in the description of the present invention,  
a "biofilm-resistant" device or surface is defined as a  
surface or device that will prevent the adherence or  
25 growth of organisms that produce polysaccharide-rich  
(about 50% or greater polysaccharide) formations, such as  
those formations generally referred to as a glycocalyx.  
Organisms that produce such a glycocalyx include the  
Staphylococcal organisms, particularly the *S. aureus* and  
30 *S. epidermidis* species. However, any organism that  
produces a polysaccharide-rich material would be equally  
inhibited by the herein described devices, surfaces,  
pharmaceutical preparations and methods.

35 The present methods are particularly efficacious for  
inhibiting polysaccharide-rich glycocalyx formation at a  
catheter port. The method in one embodiment comprises

-11-

flushing the catheter periodically with a preparation including a glycocalyx-inhibiting concentration of at least one of EDTA and minocycline, pharmacologically acceptable carrier solution. In one aspect of the method, the glycocalyx-inhibiting concentration of EDTA in the flushing solution is between about 0.01 mg/ml and about 100 mg/ml. The most preferred concentration of EDTA is about 30 mg/ml. According to one aspect of the described method, the catheter may be described as a tunneled catheter or an untunneled catheter. As part of a catheter maintenance regimen, the catheter most preferably is to be flushed with the aforescribed preparation at least once every about 24 to about 48 hours.

15

In still another aspect of the method, the pharmaceutical preparation includes minocycline. Where included, the glycocalyx-inhibiting concentration of minocycline constitutes a concentration of between about 0.001 mg/ml and about 100 mg/ml. The most preferred concentration of minocycline is about 3 mg/ml.

20

Particularly stated, the method for eliminating microbial glycocalyx formation, particularly polysaccharide-rich (Staphylococcal) glycocalyx formation, at a catheter lumen comprises preparing a solution comprising minocycline and EDTA in a carrier solution to provide an M-EDTA preparation, and flushing the catheter with a therapeutically effective amount of the M-EDTA preparation sufficient to reduce a polysaccharide glycocalyx. In one embodiment, the M-EDTA preparation includes a concentration of minocycline of between about 0.001 to about 100 mg/ml (preferably between about 2 and about 9 mg/ml) and between about 10 to about 100 mg/ml (preferably between about 20 to about 60 mg/ml) EDTA. The therapeutically effective amount of the aforescribed M-EDTA preparation would, therefore,

25

30

35

-12-

constitute between about 1 to about 10 ml (preferably about 2 to about 3 ml) of the aforescribed solution.

According to the method, a volume of about 3 ml of  
5 the aforescribed M-EDTA preparation containing about 30  
mg/ml EDTA and about 3 mg/ml minocycline is used per  
flush of a catheter or device, depending on the volume of  
the catheter or device being monitored. For example, a  
standard size tunneled CVC catheter (Hickman/Brovia) is  
10 to be flushed periodically at least once every about 24  
hours to about 48 hours with between about 2 to about 3  
ml of the M-EDTA preparation. In a preferred aspect of  
the method, the catheter is to be flushed more  
frequently, such as at least once every about 4 hours  
15 with the herein described preparations of M-EDTA.

The M-EDTA preparation will remain therapeutically  
effective for use as a catheter-flushing agent stored at  
a refrigerated temperature for at least 1 month after  
20 formulation. In use, the M-EDTA solution should be  
brought to room temperature before use on an animal or  
patient.

The aforescribed preparations have been found  
25 effective in preventing the adherence and colonization of  
catheter surfaces by *S. aureus*, *S. epidermidis*, and  
fungi, as well as effective in both treating and  
eliminating already formed glycocalyx formations of these  
infectious organisms.

30

The anti-microbial resistant medical devices of the  
present invention are further described as a medical  
device that is processed to include a coating of  
minocycline, of EDTA or of a combination of M-EDTA. Such  
35 a coating would be particularly efficacious for medical  
devices that include at least one opening or portal, as  
the coating is shown by the present inventors to be

-13-

effective for maintaining the patency of such medical device openings as that characteristic of an indwelling catheter *in vivo*. The most preferred embodiments of the devices include a coating of M-EDTA. Coating solutions  
5 of the M-EDTA include about 60 mg minocycline and about 60 mg EDTA per ml.

The following abbreviations are used in the description of the present invention:

10

CVC = Central Venous Catheters  
MRD = Modified Robbins Device  
M-EDTA = minocycline-EDTA mixture  
D<sub>10</sub>/W = 10% Dextrose and Water

15

#### BRIEF DESCRIPTION OF THE DRAWINGS

**Figure 1** - Scanning electron microscopy picture showing staphylococci and biofilm from a control catheter segment that was exposed to slime producing *S. epidermidis* and later immersed in Dextrinase for 24 hours. (Example 6 results.)  
20

**Figure 2** - Scanning electron microscopy picture showing a layer of biofilm from a catheter segment that exposed to slime producing *S. epidermidis* and later immersed in Urokinase for 24 hours. (Example 6 results.)  
25

**Figure 3** - Scanning electron microscopy picture showing a representative clear surface from a catheter segment exposed to slime producing *S. epidermidis* and later immersed in EDTA for 24 hours. The white particles are dust particles. (Example 6 results.)  
30

**Figure 4** - A scanning electron micrograph at high magnification showing coccal forms in a biofilm layer from a catheter segment coated with control solution  
35

-14-

(saline) and later exposed to slime producing *S. epidermidis*. (Example 7 results.)

5       **Figure 5** - Lower magnification from a different area  
of the catheter of Figure 4 showing coccal forms and  
biofilm. (Example 7 results.)

10       **Figure 6** - Micrograph of a catheter surface  
pretreated with dextrinase. A scanning electron  
micrograph picture showing a catheter surface pretreated  
or coated with dextrinase, upon exposure to  
staphylococci. The micrograph shows a thick biofilm  
layer with many coccal formations. These coccal  
formations are indicative of staphylococcal colonization.

15

**Figure 7** - Electron micrograph demonstrates  
formation of fibrous glycocalyx on the surface of a  
control (saline-treated) catheter segment - before  
flushing with saline for 4 hours.

20

**Figure 8** - Electron micrograph demonstrates presence  
of deranged fibrous glycocalyx on the surface of a  
minocycline coated catheter segment - before flushing  
with saline for 4 hours.

25

**Figure 9** - Electron micrograph demonstrates fibrous  
glycocalyx on the surface of a control (saline-treated)  
catheter segment - after flushing with saline for 4  
hours.

30

**Figure 10** - Electron micrograph demonstrating  
fibrous glycocalyx on the surface of a minocycline-coated  
catheter segment - after flushing with saline for 4  
hours.

35

**Figure 11** - EDTA Stability (A) and Minocycline  
Stability (B).



DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention provides pharmaceutically effective formulations of minocycline, EDTA and combinations thereof. These formulations have been found by the present inventors to be particularly useful in preventing the formation of the "biofilm" or polysaccharide-rich glycocalyx that typically accompanies microbial surface colonization. In particular, the formulations are most effective in breaking down polysaccharide-rich glycocalyx formations and in inhibiting their formation. This feature makes the preparations of the present invention potentially useful in the treatment of staphylococcal infections where a polysaccharide-rich glycocalyx has formed or may potentially be formed, as well as in the prevention and treatment of *Staphylococcal* and *Candida* infection.

The present invention also provides M-EDTA-treated or coated medical devices, such as catheters, that prevent staphylococcal or fungal colonization.

The minocycline (M) used in the studies described in the present disclosure was obtained from Lederle (Minocin® (intravenous, 100 mg, Carolina, Puerto Rico). The disodium-EDTA used in the studies described in the present disclosure was obtained from Abbott Co. (Endrate® (Intravenous 150 mg/ml) Chicago, IL). A Modified Robbin's Device, a screening tool customarily used and accepted as predictive of catheter use in humans<sup>15,16</sup>, was used in the present study of the M-EDTA pharmaceutical preparations described. The model was constructed at M.D. Anderson Cancer Center in Houston, Texas.

The following agents were used in the studies disclosed herein:

-16-

SUBSTANCE	BRAND NAME	SOURCE	LOCATION
Urokinase	Abbokinase	Abbott Laboratories	Chicago, IL
Heparin	--	Sigma Chemical Co.	St. Louis, MO
Saline	0.09 Sodium Chloride (injection U.S.P.)	Baxter Healthcare Corp.	Deerfield, IL
Dextrinase	--	Sigma Chemical Co.	St. Louis, MO
Vancomycin	Lyphocin Intravenous, 1 gram	Lyphomed	Rosemont, IL
Trypticase Soy broth	--	DIFCO Laboratories	Detroit, MI

-17-

Even though the invention has been described with a certain degree of particularity, it is evident that many alternatives, modifications, and variations will be apparent to those skilled in the art in light of the present disclosure. Accordingly, it is intended that all such alternatives, modifications, and variations which fall within the spirit and the scope of the invention be embraced by the defined claims.

The following examples are presented to demonstrate preferred embodiments of the invention, but should not be construed as limiting the claims thereof.

It should be appreciated by those of skill in the art that the technique disclosed in the examples which follow represent techniques discovered by the inventors to function well in the practice of the invention, and thus can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiment which are disclosed and still obtain like or similar results without departing, again, from the spirit and scope of the present invention.

**EXAMPLE 1 - PREPARATION OF M-EDTA**  
**PHARMACEUTICAL PREPARATION**

The present example provides a detailed description of how the M-EDTA pharmaceutical preparation was prepared for use as a catheter or medical device flushing solution. EDTA was obtained from Sigma. Minocycline was obtained from Lederle.

The M-EDTA solution was prepared as follows so as to achieve a concentration of about 3 mg/ml minocycline and

-18-

about 30 mg/ml EDTA in a sterile saline solution. Separate solutions of EDTA (60 mg/ml) and minocycline (3 mg/ml) were prepared in saline. The EDTA was reconstituted from 200 mg/ml Edetate Calcium Disodium (Versenste®, 3M Riker, Northridge, CA) or reconstituted from Edetate Disodium (150 mg/ml parenteral concentrate (Endtrate®, Abbott, Chicago, IL, or Disotate®, Forest, Maryland Heights, MO). Alternatively, the 60 mg/ml of EDTA could be reconstituted from EDTA powder (Sigma Chemical Co., St. Louis, MO). Minocycline was obtained from Lederle and combined with a volume of saline sufficient to constitute about 3 mg/ml minocycline.

The 6 mg/ml minocycline and 60 mg/ml EDTA solutions were mixed in equal volumes to constitute a 3 mg minocycline and 30 mg EDTA/ml solution. The solution was then brought to a physiologically acceptable pH of about 7.4. The solution was stored in a sterile container.

Once formulated, the M-EDTA may be stored refrigerated at 4°C until use. It is contemplated that so formulated, the solution will remain chemically stable and pharmacologically active for at least 1 month at 4°C. The preparation is also very stable at room temperature (37°C) for at least 72 hours (Table 1 and Figure 11). The preparation should be at room temperature before administration to a patient or animal.

-19-

Table 1. Percentage of Initial Concentration Remaining\* of Calcium Disodium Versenate (EDTA) 30.0 mg/mL and Minocycline Hydrochloride 3 mg/mL in a Catheter Flush Solution. Detected by High Power Liquid Chromatography.

		Storage time (hr)							
5	Temperature								
	(C)	0	6	24	72	120	168		
10	EDTA								
	37	100.0±0.5	99.9±0.6	100.3±0.2	97.9±0.4	99.0±0.5	96.9±0.2		
	25	100.0±0.5	102.1±0.3	100.9±0.0	100.1±0.1	100.4±0.2	100.5±0.2		
	4	100.0±0.5	100.2±0.1	100.8±0.2	101.7±0.8	100.3±0.1	100.9±0.4		
	Minocycline Hydrochloride								
	37	100.0±0.2	99.76±0.0	96.0±1.3	79.9±0.7	65.4±1.0	53.5±1.3		
	25	100.0±0.2	100.5±1.9	99.4±0.8	98.7±0.5	96.8±0.5	93.8±0.6		
	4	100.0±0.2	98.9±0.4	99.7±0.5	98.8±0.7	98.3±0.6	99.8±0.1		

\* Mean of duplicate determinations ± S.E.M.

15

-20-

EXAMPLE 2THE MODIFIED ROBBINS DEVICE MODEL

5           The present example is provided to describe the study model employed for illustrating the antimicrobial and therapeutic utility of the minocycline and EDTA preparations of the present invention.

10           An *in vitro* model, the Modified Robbin's Device (MRD), was used to study the formation of biofilm and colonization of catheter segments of *S. epidermidis*. This is a well established model that is described in Nickel *et al.*<sup>15</sup> and Evans and Holmes<sup>16</sup>, and provides a  
15 study model recognized by those of skill in the art as predictive of *in vivo* effects at a catheter surface.

          The MRD is constructed of an acrylic block, 42 cm long, with a lumen of 2x10 mm. The MRD is made of  
20 twenty-five evenly spaced specimen plugs each connected to a catheter latex segment whose anterior surface (0.3 cm<sup>2</sup>) comes in contact with the flushed infusate coming from a connected tubing and infusion bag. Several studies were conducted using this model, which are  
25 outlined in the following examples.

EXAMPLE 3 - INHIBITION OF *S. EPIDERMIDIS*

          The present example is provided to demonstrate the  
30 utility of the present invention for inhibiting *S. epidermidis* in and on a medical device, such as a catheter. The model described in Example 2 was used in the present study. These results demonstrate the utility of the invention for treating and maintaining catheter  
35 patency *in vivo*, and more specifically for inhibiting *S.*

-21-

*epidermidis* adhesion and glycocalyx formation at a catheter surface.

Catheter segments were placed in the specimen plugs of the Modified Robbins Device described in Example 2. After placing the catheter segments in the specimen plugs, the entire apparatus was sterilized with ethylene oxide. A 500 ml 10% dextrose/water bag was infected with  $4 \times 10^8$  CFU/ml of *S. epidermidis* (to produce  $8 \times 10^5$  CFU per ml of D<sub>10</sub>/W). The infected infusate was flushed through the MRD for 3 hours at a 50 ml/hr (using a peristaltic pump). In order to remove all free floating and loosely adherent staphylococci, the infected bag was removed and a new sterile bag (of D<sub>10</sub>/W) was used to flush the MRD. The MRD was flushed with sterile D<sub>10</sub>/W for 24 hours at 40 mls/hr. Following this, catheter segments of equal size were treated with different agents by placing them in tubes containing one of the following solutions:

1. Urokinase (5000 units/ml);
2. Heparin (1000 unit/ml);
3. EDTA (50 mg/ml); and
4. Trypsin (20,000 units/ml).

Representative catheter segments were then removed (in a sterile manner) at 4 and 24 hours and quantitatively cultured using the scrape-sonication technique described by Khoury et al. (1991)<sup>14</sup> to isolate organisms adherent to catheter surfaces. The Khoury et al. reference is specifically incorporated herein by reference for this purpose. The experiment was done at 37°C.

The results from this study are presented at Table 2. The results demonstrate that treatment of catheter surfaces with EDTA was effective in preventing

-22-

adherent *S. epidermidis* colonies on a catheter surface after only 4 hours of treatment. In contrast, urokinase, heparin and trypsin treatment of the catheter segments was significantly less effective at inhibiting adherent *S. epidermidis* colony formation and adherence after 4 hours of treatment.

TABLE 2  
NO. OF ADHERENT *S. EPIDERMIDIS* COLONIES  
OBTAINED FROM 0.3 CM<sup>2</sup> CATHETER SURFACES

Agent Used	After 4 hrs. of treatment	After 24 hrs. of treatment
Urokinase	310	40
Heparin	545	20
EDTA	0	0
Trypsin	150	5

EXAMPLE 4 - M-EDTA AND THE  
PREVENTION OF BIOFILM FORMATION

20

The present example is provided to demonstrate the utility of the M-EDTA preparation in preventing glycocalyx-rich biofilm formation at the surface of a medical device, as well as to demonstrate the anti-staphylococcal activity of minocycline and EDTA preparations.

25

The method of Example 3 was used with the following modifications:

30

1. A more intense exposure to staphylococci (*S. epidermidis* and *S. aureus*) was achieved by flushing the MRD for 6 hours (instead of 3 hours in Example 3) with  $3 \times 10^6$  CFU of staphylococci/ml of D<sub>5</sub>/W; and

35



-23-

2. The growth of adherent staphylococci to the catheter segments was promoted and achieved by exposing the catheter segments at 37°C to a 10% broth solution (prepared by adding 1 ml of trypticase soy broth to 9 ml of sterile H<sub>2</sub>O) of EDTA (30 mg/ml of 10% broth solution), heparin (100 units/ml of 10% broth), urokinase (5,000 units/ml of 10% broth), minocycline (3 mg/ml of 10% broth), mino/EDTA (3 mg/30 mg per ml of 10% broth), vancomycin (3 mg/ml of 10% broth), vancomycin/heparin (3 mg vancomycin plus 100 units heparin/ml of 10% broth), or D<sub>5</sub>/10% broth (50 mg/ml of 10% broth solution).

The results from these studies are demonstrated at Table 3 (*S. epidermidis*) and Table 4 (*S. aureus*).

TABLE 3

NO. OF ADHERENT *S. EPIDERMIDIS* COLONIES  
OBTAINED FROM 0.3 CM<sup>2</sup> CATHETER SURFACES

Agent Used	After 4 hrs. of treatment	After 24 hrs. of treatment
Urokinase	>5x10 <sup>3</sup>	>5x10 <sup>3</sup>
Heparin	>5x10 <sup>3</sup>	>5x10 <sup>3</sup>
EDTA	800	20
Minocycline	10	0
Minocycline/EDTA	0	0
Vancomycin	55	85
Vancomycin/Heparin	445	40
D <sub>5</sub> /10% broth	>5x10 <sup>3</sup>	>5x10 <sup>3</sup>

As demonstrated in Table 3, the urokinase, heparin and dextrose solutions alone were equally ineffective in preventing and eradicating *S. epidermidis* adherence after 4 or 24 hours of catheter treatment. The minocycline and minocycline/EDTA provided effective prevention and

-24-

irradication of *S. epidermidis* adhesion after only 4 hours of treatment. Minocycline/EDTA was slightly more effective than minocycline alone at 4 hours. EDTA alone and vancomycin/heparin provided minimal prevention at 4 hours but were more effective after 24 hours. Vancomycin alone provided equal partial prevention at 4 and 24 hours. M-EDTA was superior to all preparations examined, including vancomycin, vancomycin/heparin, minocycline or EDTA alone.

10

**TABLE 4**  
**NO. OF ADHERENT *S. AUREUS* COLONIES**  
**OBTAINED FROM 0.3 CM<sup>2</sup> CATHETER SURFACES**

Agent Used	After 4 hrs. of treatment	After 24 hrs. of treatment
Urokinase	$>5 \times 10^3$	$>5 \times 10^3$
Heparin	256	$>5 \times 10^3$
EDTA	750	30
Minocycline	0	0
Minocycline/EDTA	0	0
Vancomycin	605	230
Vancomycin/Heparin	140	185
D <sub>5</sub> /10% broth	$>5 \times 10^3$	$>5 \times 10^3$

\* All staphylococcus isolates were bloodstream slime-producing isolates obtained from human patient cases with catheter-related bacteremia.

Table 4 demonstrates that minocycline and minocycline/EDTA solutions were the most effective inhibitors of *S. aureus* adhesion, with 0 adherent colonies being observed after 4 hours of treatment. EDTA alone, vancomycin alone and vancomycin/heparin were significantly less effective for preventing adherent *S.*

-25-

*aureus*. These later three preparations had some partial anti-adherent activity, particularly after 24 hours of treatment.

5           These data (Table 3 and Table 4) demonstrate that minocycline alone or in combination with EDTA was effective for inhibiting *S. epidermidis* and *S. aureus* adherence and colonization of a catheter surface.

10                           EXAMPLE 5 - M-EDTA AND THE  
                          INHIBITION OF *C. albicans* ADHESION

          The present example is provided to demonstrate the utility of the M-EDTA formulation in the inhibition of  
15   other glycoalkyx and biofilm-forming microorganisms, such as *C. albicans*.

          The M-EDTA flush formulation described in Example 1 was employed in the present example. The method employed  
20   was the same as that described at Example 4, with the following modifications. The organism used was a *C. albicans* obtained from the bloodstream of a patient with catheter-related candidemia. The infected infusate consisted of D<sub>5</sub>/W with 4x10<sup>2</sup> CFU of *C. albicans* per ml  
25   flushed through the MRD for 6 hours. Results from the study are presented in Table 5.

-26-

TABLE 5  
NO. OF ADHERENT *C. ALBICANS*  
OBTAINED FROM 0.3 CM<sup>2</sup> CATHETER SURFACES

Agent Used	After 4 hrs. of treatment	After 24 hrs. of treatment
5 Urokinase	$>5 \times 10^3$	$>5 \times 10^3$
Heparin	$>5 \times 10^3$	$>5 \times 10^3$
EDTA	1060	155
Minocycline	190	535
Minocycline/EDTA	0	0
10 D <sub>5</sub> /10% broth	$>5 \times 10^3$	$>5 \times 10^3$
Vancomycin/heparin	$>5 \times 10^3$	$>5 \times 10^3$
Vancomycin	470	$>5 \times 10^3$

15           This example demonstrates minocycline/EDTA as a  
unique antistaphylococcal and antifungal agent.  
Vancomycin (a standard antistaphylococcal agent) when  
used alone or with heparin failed to have any anti-*C.*  
20           *albicans* activity and was not different from dextrose,  
urokinase or heparin solutions against *C. albicans*.

EDTA alone had some anti-*C. albicans* activity after  
24 hours and minocycline alone had some activity at 4 and  
probably 24 hours. The combination of minocycline and  
25           EDTA (M-EDTA) provided a synergistic enhancement of anti-  
*C. albicans* activity, demonstrating an essentially total  
inhibitory effect against fungal adherence after 4 and 24  
hours exposure. Therefore, M-EDTA is unique in  
preventing staphylococcal and *Candida* adherence to  
30           catheter surfaces (Staphylococci and *Candida* contributing  
to 95% to 100% of the pathogenic microbiology of  
catheter-related infections).

          These results demonstrate that the solutions of a  
35           mixture of minocycline and EDTA provide a more effective

-27-

and rapidly-acting preparation for the prevention of *S. epidermidis*, *S. aureus*, and *C. albicans* adhesion to a catheter surface than any other thrombolytic (urokinase), anticoagulant (heparin, EDTA), or antistaphylococcal preparation (minocycline, vancomycin, vancomycin/heparin).

**EXAMPLE 6 - *S. epidermidis* BIOFILM FORMATION AND HEPARIN, UROKINASE AND DEXTRANASE TREATMENT**

10

The present example is provided to examine the relative *S. epidermidis* glycocalyx biofilm-destroying activity of heparin, urokinase and dextranase as assessed by scanning electron microscopy of an *S. epidermidis*-colonized catheter surface.

15

Scanning electron microscopy was done on various segments of a catheter exposed to *S. epidermidis* and then later exposed to heparin, urokinase or dextranase for 24 hours. A reduction in biofilm (glycocalyx) was noted on colonized catheter surfaces exposed to EDTA for 24 hours, compared to colonized surfaces later exposed to heparin, urokinase, or dextranase for 24 hours (Figure 1 = Dextranase; Figure 2 = Urokinase; Figure 3 = EDTA; Figure 4 = Saline).

20  
25

**EXAMPLE 7 - PRETREATMENT OF CATHETER SURFACES WITH EDTA, Dextranase OR SALINE AND *S. epidermidis* BIOFILM FORMATION**

The present example is provided to demonstrate the effect of chemically pretreating a catheter surface with EDTA or dextranase, compared to a saline control, on the formation of polysaccharide-rich biofilm formation, such as that characteristic of *S. epidermidis*, and the adhesion of these organisms to a catheter surface.

30  
35

-28-

Catheter surfaces were coated with EDTA, dextranase or control (saline), at the concentrations described in Example 5, and then exposed to slime producing *S. epidermidis*.

5

No biofilm or organisms were observed on EDTA coated surfaces. However, biofilm formation was observed on catheter surfaces pretreated with dextranase (Figure 4 and 5 = saline; Figure 3 = EDTA; Figure 6 = Dextranase pretreated).

10

EXAMPLE 8 - MINOCYCLINE COATING OF  
A CATHETER AND MICROBIAL COLONIZATION

The present example is provided to demonstrate the anti-microbial colonization effect of the use of minocycline at a catheter surface.

15

Catheter surfaces were coated with minocycline, vancomycin or control cement with H<sub>2</sub>O. Catheter surfaces were then exposed to clinical staphylococci isolates. The Modified Robbin's Device was employed in this study (See Example 2. The Modified Robbin's Device simulates a vascular catheter, and therefore provides a model predictive of *in vivo* effects.

20

25

One gram of methylmethacrylate (cement) was mixed with 0.5 ml of sterile H<sub>2</sub>O and one of the following:

30

1. 60 mg of minocycline
2. 60 mg of vancomycin
3. control (cement + H<sub>2</sub>O alone)

Equal amounts of cement alone or with minocycline or vancomycin were put in the lumen of catheter latex segments in a specimen plug of the Modified Robbin's

35

-29-

Device. Twenty-four hours later, a one-liter infusate bag made of 5% dextrose in water was infected with 5 ml of  $10^5$  to  $10^8$  colony forming units (CFU) per ml of slime producing *Staphylococcus epidermidis* strains obtained from the bloodstream of patients with catheter related bacteremia. Using a peristaltic pump, the infected infusate was run for 2 hours at a rate of 60 ml/hr through the catheter segments of the Modified Robbin's Device.

Each catheter segment was made of 30 mm<sup>2</sup> silicone with a lumen filled with cement. At the end of 2 hours, some catheter segments (control and antibiotics coated) were taken out from specimen plugs and the cement in the lumen was removed, then the surface that was exposed to the infected fluid was cultured semiquantitatively using the roll-plate technique. Other segments were left behind and flushed with saline solution for 4 hours, then cultured by roll-plate.

Electron microscopy was used to document the adherence of staphylococci and the formation of biofilm layer on the surface of control uncoated catheter segments. Leaching of antibiotics from the cement was demonstrated to occur for at least one week by determining the inhibition around disc-shaped pieces of cement placed on blood agar plates that had been inoculated with bacteria. Coating of the catheter segments with antibiotics was demonstrated by the zone of inhibition that continued to form for at least one week around the disc-shaped catheter segments (without cement) placed on agar plates that had been inoculated with bacteria. The results from this study are presented in Table 6.

-30-

TABLE 6  
NO. COLONIES OF *S. EPIDERMIDIS*  
FROM 30 MM<sup>2</sup> CATHETER SURFACE

Coating	Before Flush	After Flush
Control	336	128
Vancomycin	174	111
Minocycline	48	15

10 Catheter segments coated with minocycline had a significantly lower number of adherent *Staphylococcus epidermidis* colonies, compared to control and vancomycin coated catheter segments (see Table 6). However, fibrous glycocalyx was not inhibited on the minocycline-coated catheter surfaces. The scanning electron microscopic figures also evidenced these findings. See Figure 7 - shows fibrous glycocalyx on the surface of a control catheter segment - before flush; Figure 8 - shows some deranged fibrous glycocalyx on the surface of minocycline coated catheter segment - before flush; Figure 9 - shows fibrous glycocalyx on the surface of another control (saline) catheter segment after flush; and Figure 10 - shows fibrous glycocalyx on the surface of minocycline coated catheter segment after flush.

25 These data demonstrate that the coating of catheters with minocycline alone significantly reduced staphylococcal adherence. Fibrous glycocalyx formation is not inhibited with minocycline-coated surfaces.

30 EXAMPLE 9 - STABILITY OF MINOCYCLINE  
AND EDTA PHARMACEUTICAL PREPARATIONS

The present studies will be conducted to characterize the stability of the pharmaceutical M-EDTA flushing solutions of the present invention. The M-EDTA



-31-

solutions are expected to retain their potency for relatively long periods of time when stored refrigerated at about 4°C, i.e., for at least 1 month.

5           The solutions of the present invention have been examined for retained potency at room temperature (37°C). The M-EDTA solutions have been observed to retain relatively full anti-microbial and anti-fungal potency for at least 72 hours at room temperature. It is  
10           therefore expected that the formulation has a shelf life that renders it suitable for routine hospital use (Table 1 and Figure 11).

#### EXAMPLE 10

15           COMPARATIVE CLINICAL TRIAL OF M-EDTA AND  
HEPARIN FOR THE PREVENTION OF CATHETER-RELATED INFECTIONS

          The present example outlines a study wherein the relative effectiveness of an M-EDTA catheter flushing  
20           solution will be compared to a heparin flushing solution (a currently used standard preparation) for the prevention of catheter-related infections and occlusions in humans.

25           The objective of these studies is to further document the utility of the M-EDTA flush solution as compared to a heparin flush solution in preventing infection and/or occlusion in central venous catheters (CVC).

30

          Eligibility for enrollment into these studies will be based on the following inclusion/exclusion criteria:

-32-

**Inclusion Criteria**

1. Patients must have a new ( $\leq 7$  days old) functioning central venous catheter, utilized for infusion of chemotherapy, blood products, or other intermittent infusions.
2. Patients must be able to return to the outpatient clinic for evaluation in case of CVC occlusion or occurrence of fever.
3. Patients must have life expectancy for the planned duration of the study and must have catheter in place for study duration (study duration for a single patient is 6 months).
4. Catheters in the percutaneous/tunneled group will be limited to Hickman/Broviac.

**Exclusion Criteria**

1. Patients with an occluded central venous catheter.
2. Patients with any existing local or systemic catheter infection.
3. Patients with triple lumen catheters.
4. Patients with polyurethane or teflon catheters.
5. Patients currently taking warfarin.
6. Patients requiring previous catheter removal due to venous thrombosis.

-33-

7. It must be expected that the dwell time of 4 hours will not interfere with routine treatment of the underlying disease.

5           8. Patients with Groshong catheters.

**Treatment Plan:** Patients will be randomly assigned and in double blind manner to have their CVC flushed with either M-EDTA or heparin according to the following:

10

1. Tunneled CVC (Hickman/Broviac) will receive either
  - (a) two mls of M-EDTA (containing 3 mg of minocycline and 30 mg EDTA/ml) q daily
  - (b) two mls of Heparin (100U/ml) q daily.

15

2. Infusion ports will receive either
  - (a) two mls of M-EDTA (3 mg minocycline and 30 mg EDTA/ml) q 3 weeks
  - (b) two mls of Heparin (100U/ml) q 3 weeks

20

**Endpoints and Treatment Evaluation:** All patients will be followed up for 6 months and will be evaluated for 2 endpoints: catheter infection/colonization and occlusion. Catheter infection will include local CVC-related infection or systemic catheter-related septicemia. Catheter colonization will include positive quantitative catheter culture (flush technique) or positive quantitative blood culture through the CVC in the absence of a positive peripheral blood culture or clinical manifestations of sepsis (fever, chills or hypotension). Patients in the study who develop fever will be evaluated, and simultaneous quantitative blood cultures through CVC and peripheral vein conducted. Catheter occlusion will be categorized as complete or

25  
30  
35

partial depending on whether one cannot withdraw blood,

-34-

infuse fluids through the CVC, or both. This subgroup of infected catheters will be analyzed separately.

5 Statistical Considerations: Based on a recent surveillance study conducted by the inventors (see Table 7), the rate of CVC-related sepsis in pediatric oncology patients ranges from 15% - 20.5% (see Table 6). These same ranges will be employed in further establishing the clinical utility of the treatment in adult patients.

10

-35-

**TABLE 7**  
**INFECTION RATES ASSOCIATED WITH HICKMAN/BROVIAC**  
**CATHETERS AND IMPLANTABLE PORTS IN PEDIATRIC ONCOLOGY**  
**PATIENTS, PER 100 CATHETERS**

Type of Infection	Hickman/Broviac (N)	Port (N)	Total (N)
<b>LOCAL CATHETER INFECTION</b>			
Exit site or port infection	17.9 (7)	3.0 (3)	7.2 (10)
Extraluminal infection (tip $\geq 15$ cfu)	0 (0)	0 (0)	0 (0)
Infection secondary to intraluminal colonization	7.7 (3)	3.0 (3)	4.3 (6)
Tunnel tract infection	2.6 (1)	N/A	0.7 (1)
<b>Total</b>	<b>28.2 (11)</b>	<b>6.0 (6)</b>	<b>12.2 (17)</b>
<b>CATHETER-RELATED SEPSIS</b>			
Definite	7.7 (3)	2.0 (2)	3.6 (5)
Probable & physician diagnosed	12.8 (5)	13.0 (13)	12.9 (18)
<b>Total</b>	<b>20.5 (8)</b>	<b>15.0 (15)</b>	<b>16.5 (23)</b>

# Catheters                      N = 39                      N = 100                      N = 139

-36-

The results from this study will be employed in the development of a clinical protocol for the treatment and infection-free maintenance of indwelling catheters in humans.

5

EXAMPLE 11 - PREPARATION OF  
M-EDTA-COATED DEVICES FOR IN VIVO USE

The present example is provided to demonstrate the utility of the M-EDTA solution as a coating material for medical devices, most particularly catheters.

Any of a variety of coating techniques may be used for imparting a protective covering of the M-EDTA solution to a device. By way of example, such methods include emersion of a medical device, such as a catheter, into a solution of minocycline and EDTA. This example provides a description of how these particular M-EDTA coated catheters were prepared.

20

Bioguard Cook Catheters with TDMACC surfactant were immersed in antibiotic solutions containing the following:

- 25           1.    60 mg of Minocycline plus 60 mg of EDTA/ml
2.    60 mg of Minocycline/ml
3.    60 mg of EDTA/ml

Catheters were immersed in each of the three solutions listed above for about 15 minutes. Bioguard Cook catheters not treated with any of the 3 solutions listed above (which are not coated by antimicrobials) were used as negative controls. Arrow Gard catheters coated with chlorhexidine and silver sulfadiazine were used as positive control devices. The Arrow Gard catheter is coated with antimicrobials. This catheter is

35

-37-

described by Maki et al. in a clinical study, and reportedly decreased the rate of catheter-related bloodstream infection by five-fold as compared to a standard polyurethane triple-lumen CVC without a chlorhexidine and silver sulfadiazine coating.

#### Other Coating Methods for Medical Devices

As noted, preparations of the present invention may be advantageously used as a coating preparation for treating the surfaces of a medical device. The medical devices which are amendable to coatings with the subject M-EDTA preparations generally have surfaces composed of thermoplastic or polymeric materials such as polyethylene, Dacron, nylon, polyesters, polytetrafluoroethylene, polyurethane, latex, silicone elastomers and the like. Devices with metallic surfaces are also amenable to coatings with the disclosed combinations. Such devices, for example indwelling catheters of types listed herein, can be coated by cement mixture containing the subject antibiotic compounds. Alternatively, devices that include a surfactant, such as the Bioguard Cook catheters, may be used whereby the surfactant at the surface of the device allows for the coating of the material onto the device. Particular devices especially suited for application of the M-EDTA preparation include intravascular, peritoneal, pleural and urological catheters; heart valves; cardiac pacemakers; vascular shunts; and orthopedic, intraocular, or penile prosthesis.

Various methods can be employed to coat the surfaces of medical devices with the M-EDTA coating preparation described herein (60 mg EDTA/60 mg minocycline). For example, one of the simplest methods would be to flush the surfaces of the device with the M-EDTA preparation.

-38-

Generally, coating the surfaces by a simple flushing technique would require convenient access to the implantable device. For example, catheters, are generally amenable to flushing with a solution of EDTA and minocycline. For use as coating solutions, the effective concentration of minocycline would range from about 0.001 to 100 mg/ml, preferably about 60 mg/ml; and about 1 to 100 mg/ml EDTA, preferably about 60 mg/ml EDTA. The coating solution would normally be further composed of a sterile water or a sterile normal saline solutions.

A preferred method of coating the devices would be to first apply or adsorb to the surface of the medical device a layer of tridodecylmethyl ammonium chloride (TDMAC) surfactant followed by a coating layer of the M-EDTA preparation. This method for coating a device with M-EDTA provides for first absorbing to the catheter surface a cationic surfactant, such as TDMAC, to medical devices having a polymeric surface, such as polyethylene, silastic elastomers, polytetrafluoroethylene or Darcon, by soaking in a 5% by weight solution of TDMAC for 30 minutes at room temperature. The device should then be air dried, and rinsed in water to remove excess TDMAC. Alternatively, TDMAC pre-coated catheters are commercially available; for example, arterial catheters coated with TDMAC are available from Cook Critical Care, Bloomington, Indiana. The device carrying the adsorbed TDMAC surfactant coating can then be incubated in a solution of the M-EDTA combination for between about 15 minutes and an hour, washed in sterile water to remove unbound M-EDTA and stored in a sterile package until implantation. In general, the soaking solution of M-EDTA includes between about 10 mg/ml - 100 mg/ml EDTA (preferably about 60 mg/ml) and between about 10 mg/ml -



-39-

100 mg/ml minocyclines (preferably about 60 mg/ml) in an aqueous pH 7.4-7.6 buffered solution or sterile water.

Alternative processes and reagents for bonding an agent contained in a solution to a surfactant-coated implantable medical device are provided in U.S. Patent Nos. 4,442,133, 4,678,660 and 4,749,585, which patents are incorporated herein in their entirety by reference for this purpose. A further method useful to coat the surface of a medical device with an M-EDTA preparation involves first coating the selected surfaces with benzalkonium chloride followed by ionic bonding of the M-EDTA. See, e.g., Solomon, D.D. and Sherertz, R.J. (1987)<sup>17</sup> and U.S. Patent No. 4,442,133<sup>18</sup>.

15

Other methods of coating surfaces of medical devices with antibiotics are taught in U.S. Patent No. 4,895,566 (a medical device substrate carrying a negatively charged group having a pKa of less than 6 and a cationic antibiotic bound to the negatively charged group); U.S. Patent No. 4,917,686 (antibiotics are dissolved in a swelling agent which is adsorbed into the matrix of the surface material of the medical device); U.S. Patent No. 4,107,121 (constructing the medical device with ionogenic hydrogels, which thereafter absorb or ionically bind antibiotics); U.S. Patent No. 5,013,306 (laminating an antibiotic to a polymeric surface layer of a medical device); and U.S. Patent No. 4,952,419 (applying a film of silicone oil to the surface of an implant and then contacting the silicone film bearing surface with antibiotic powders).

These and many other methods of coating a solution to a solid surface appear in numerous patents and medical journal articles. As is evident, one of ordinary skill having benefit of this disclosure would be apprised of

-40-

several different methods of coating a medical device surface with the subject inventive minocycline and EDTA coatings.

- 5 Medical devices, particularly catheters of the type listed in Table 8, may be coated with the M-EDTA solution and then stored in a sterile packaging material until use.

10

TABLE 8

	SHORT-TERM TEMPORARY ACCESS CATHETER	LONG-TERM INDEFINITE VASCULAR ACCESS
15	Peripheral intravenous cannulas - winged steel needles - peripheral intravenous catheters	Peripherally inserted central venous catheters (PICC)
	Arterial catheters	Percutaneous nontunneled silicone catheters
20	Central venous catheters	Cuffed tunneled central venous catheters (Hickman and Broviac)
	Swan-Ganz catheters	Subcutaneous central venous ports (Infusaport, Port-a- cath, Landmark)
	Hemodialysis catheters	
	Umbilical catheters	

25

EXAMPLE 12METHOD FOR MAINTAINING CATHETER PATENCY  
WITH MINOCYCLINE-EDTA PHARMACEUTICAL PREPARATION

- 30 The present example demonstrates one embodiment of a method that may be used in maintaining the patency of an indwelling catheter in a patient. The regimen described herein is potentially applicable for use in adult

-41-

patients, as the dose of M-EDTA in the regimen exposes patients only to relatively low, pharmaceutically acceptable levels of the EDTA and minocycline, and has already been demonstrated by the inventors as effective in pediatric patients.

An indwelling catheter of a patient will be flushed with a solution of minocycline/EDTA. The "flushing" of the catheter will constitute filling the catheter with a volume of the M-EDTA solution sufficient to provide a concentration of about 9.0 mg minocycline and a concentration of about between 90 mg EDTA in the catheter. For example, assuming a catheter volume of about 2-3 ml., the solution will contain a concentration of EDTA of between about 10 mg/ml - 30 mg/ml, and a concentration of minocycline of between about 1-3 mg/ml. "Flushing" the catheter with about 3 ml of the M-EDTA solution will thereby provide a dose of between 3-9 mg minocycline and about 30 - 90 mg EDTA. The solution of M-EDTA will be prepared as outlined in Example 1.

The "flushing" of the catheter is achieved by adding between 2-3 ml of the M-EDTA solution to the catheter. The solution is then allowed to diffuse through the catheter to the patient in which it is implanted. The concentration of the EDTA and minocycline in the solution is such that the patient will be exposed only to concentrations of the agents well below pharmacologically tolerable levels.

30

The flushing of the catheter is to be repeated at periodic intervals of at least between every 24 to 72 hours (preferably, every 24 hours) to assure that infectious organisms are not allowed an opportunity to colonize the surface or initiate biofilm formation on the catheter surface.

35

-42-

EXAMPLE 13  
EFFICACY OF ANTIBIOTIC COATED CATHETERS  
AFTER GAS STERILIZATION

5           The present example is provided to demonstrate the  
stability of the coated devices to sterilization  
processes. In order to test the effect of gas  
sterilization on catheters coated with Minocycline, EDTA  
and the combination of drugs, the following studies were  
10 performed.

M-EDTA-coated catheters were prepared as described  
in Example 11. The catheters were then divided into  
three representative groups. The catheter antibiotic  
15 activity was determined in vitro by a modified Kirby-  
Bauer technique described in Sherertz et al. ((1989)  
*Antimicrob. Agents Chemother.*, 33:1174-1178), which  
reference is specifically incorporated herein by  
reference for this purpose. The first set of catheters  
20 were tested immediately after immersion without gas  
sterilization. The second set was tested 24 hours later  
without gas sterilization. The third set was tested 24  
hours after gas sterilization.

25           The modified Kirby-Bauer technique consisted of  
growing a strain of slime producing catheter-related  
bacteremic isolate of *Staphylococcus epidermidis* for 18  
hours in trypticase soy broth, then diluting the solution  
to 10 CFU ml in phosphate-buffered saline. A cotton swab  
30 was placed in the staphylococcal suspension and then  
rubbed across the surface of a trypticase soy agar plate.  
Individual catheters were cut into 20 mm lengths pressed  
into agar overlaid with *S. epidermidis* and incubated  
overnight at 37°C. Zone sizes were assessed by measuring  
35 the diameter perpendicular to the long axis of the  
catheter. The data in Table 9 demonstrates that

-43-

Catheters treated with the M-EDTA preparations maintained the greatest post-sterilization zone of inhibition (0 hours =40; 24 hours = 34).

5 For the *in vivo* studies, the catheters were cut into 2 cm segments and then emersed in 60 mg/ml EDTA, 60 mg/ml minocycline solution each and then immersed in a solution of a mixture containing 60 mg/ml mino and 60 mg/ml EDTA for 15 minutes. All catheters were allowed to dry for  
10 one hour and they were gas sterilized.

Table 9 provides the results achieved with these studies. This data demonstrates the superior anti-*S. epidermis* activity of the M-EDTA coating as compared to  
15 non-treated as well as the Arrow Gard catheters.

TABLE 9 *S. EPIDERMIDIS*  
ZONE OF INHIBITION - DIAMETER (mm)

	<u>Pre Sterilization</u>		<u>Post Sterilization</u>
	<u>0 Hrs</u>	<u>24 Hrs</u>	<u>24 Hrs</u>
20 Minocycline	36	33	18
M-EDTA	40	34	35
EDTA	5	18	10
Control	0	0	0
25 Arrow Gard*	13	15	7

\*Coated with chlorhexidine gluconate and silver sulfadiazine

30

-44-

EXAMPLE 14EFFICACY OF ANTIBIOTIC COATED CATHETERS  
AFTER GAS STERILIZATION TO *S. AUREUS*

5       The present example is provided to further demonstrate the stability of the described M-EDTA coatings to sterilization processes, such as gas sterilization, particularly as measured through the retained anti-microbial activity of the device.

10

      The protocol of Example 13 was used to prepare the catheters used in this study (using a catheter-related bacteremic strain of *S. aureus*). The 0 hour catheters, and catheters coated with minocycline or EDTA alone were  
15       not included in the study.

TABLE 10 *S. AUREUS*  
ZONE OF INHIBITION - DIAMETER (mm)

20

	<u>Pre</u> <u>Sterilization</u>	<u>Post</u> <u>Sterilization</u>
	<u>24 Hrs</u>	<u>24 Hrs</u>
M-EDTA	31	29
Control	0	0
Arrow Gard*	13	13

25

\*Coated with chlorhexidine gluconate and silver sulfadiazine

30

      The present example demonstrates that gas sterilization did not affect the antibiotic activity of minocycline-EDTA coated catheters and that these catheters were at least two times more active at inhibiting *Staphylococcus aureus* than the Arrow septic catheters.

35

-45-

EXAMPLE 15COMPARATIVE EFFICACY OF M-EDTA COATED CATHETERS  
AGAINST CATHETER RELATED MICROORGANISMS

5           The present example demonstrates the broad spectrum  
activity of M-EDTA catheters. The same zone of  
inhibition measure described in examples 13 and 14 (with  
the modified Kirby-Bauer technique) were employed using  
M-EDTA coated catheters and Arrow Gard catheters  
10 (commercially available) to examine the effectiveness of  
the various coatings against different catheter-related  
organisms such as *Staphylococcus epidermidis*,  
*Staphylococcus aureus*, *Candida albicans* and gram negative  
bacilli (*Pseudomonas aeruginosa*, *Xanthomonas maltophilia*,  
15 and acinetobacter species.) Approximately 60% of  
catheter infections are caused by *S. epidermidis*, 10% by  
*S. aureus*, 10% by *C. albicans*, 20% by gram negative  
bacilli (mostly *P. aeruginosa*, *X. maltophilia*, and  
acinetobacter species.) These studies show that  
20 catheters coated with M-EDTA have a broad spectrum  
activity against different species of bacteria and fungi  
as well as different strains of the same species. For  
purposes of the present studies, a zone of inhibition of  
≥ 15 mm is a predictor of excellent efficacy in veins. A  
25 zone of 10 - 15 mm is a predictor of moderate efficacy  
and a zone of inhibition of ≤ 10 mm is a predictor of  
poor efficacy.

***Staphylococcus epidermis***

30

The data in Table 11 demonstrates that the M-EDTA  
coated catheters has a significantly greater zone of  
inhibition to five strains of *staphylococcus epidermidis*,  
as compared to non-M-EDTA coated catheters (Arrow Gard  
35 catheters).

-46-

TABLE 11 - ZONES OF INHIBITION (mm)  
(STAPHYLOCOCCUS EPIDERMIDIS (SE) STRAINS

Strain No.	Arrow Gard	Mino/EDTA
SE 4392	14	31
SE 3996	16	29
SE 4345	17	39
SE 4023	15	29
SE 93	15	31
Mean (SD)	15.4 ( $\pm 1.1$ )	31.8 ( $\pm 4.14$ )

p = 0.001

*Staphylococcus aureus*

Table 12 sets forth data obtained employing five different strains of *Staphylococcus aureus* (SA) in the aforescribed zone of inhibition assays. The data demonstrate that the M-EDTA coated catheters provided a significantly greater zone of inhibition compared to the non-M-EDTA catheters (Arrow Gard).

TABLE 12 - ZONES OF INHIBITION - DIAMETER (mm)

Strain No.	Arrow Gard	Mino/EDTA
SA 1445	13	23
SA 1432	15	28
SA 1414	12	23
SA 48	14	23
SA 1411	12	34
Mean (SD)	13.2 ( $\pm 1.3$ )	26.2 ( $\pm 4.9$ )

p = 0.005

*Candida albicans*

Table 13 sets forth data obtained employing the organism *Candida albicans*, in the zone of inhibition



-47-

study protocol, comparing the inhibitory action of the M-EDTA and non-M-EDTA coated catheters especially.

"Ampho B" stands for a broad spectrum antibiotic (INVENTORS, PLEASE SUPPLY). The data in Table 13

5 demonstrates that the M-EDTA treated catheters had superior anti-*Candida albicans* inhibitory activity as compared to control and the three other catheter types (coatings) tested.

TABLE 13 - ZONES OF INHIBITION - DIAMETER (mm)  
*Candida albicans*

	<u>Trial #1</u>	<u>Trial #2</u>	<u>Trial #3</u>
M-EDTA	16	21	16
Minocycline	0	0	0
Control	0	0	0
Arrow Gard	10	9	9
Ampho B	ND	18	18

Table 14 sets forth data obtained in studies with  
20 five strains of *Candida albicans*, and again demonstrates  
the broad range anti-microbial activity of the M-EDTA  
coated catheters.

-48-

TABLE 14 - ZONES OF INHIBITION - DIAMETER (mm)  
(STRAINS OF *CANDIDA ALBICANS* (CA))

Strain No.	Arrow Gard	Mino/EDTA
CA 291	0	16
CA 596	10	12
CA 276	10	10
CA 267	10	13
CA 319	7	18
Mean (SD)	7.4 ( $\pm 4.3$ )	13.8 ( $\pm 3.2$ )

p = 0.030

***Acinetobacter* (Acin)**

Table 15 demonstrates the efficacy of the described M-EDTA coatings for inhibiting *Acinetobacter*.

TABLE 15 - ZONES OF INHIBITION - DIAMETER (mm)

Strain No.	M/EDTA	TMP/SMX	CFTZ	ARROW GARD
ACIN639	30	00	00	00
ACIN38B	23	30	15	05
ACIN632	24	10	00	00
ACIN633	10	15	00	09
ACIN1771	43	14	00	12
Mean*	26	14	3.0	5.2
STDEV	12	11	6.7	5.3

M = Minocycline; CFTZ = Ceftazidime;

TMP-SMX = Trimethoprin-Sulfamethoxazole

\* The efficacy of the catheter coated with M-EDTA was significantly higher than the Arrow Gard (p = 0.016)

-49-

*P. Aeruginosa (PSA) Strains*

Table 16 demonstrates the efficacy of the M-EDTA coated catheters against *P. aeruginosa* (PSA) strains.

5

TABLE 16 - ZONES OF INHIBITION - DIAMETER (mm)

Strain No.	M/EDTA	TMP/SMX	CFTZ	ARROW GARD
PSA1644	15	00	13	03
PSA2455	11	05	20	00
PSA2451	11	00	20	06
PSA2456	14	00	29	00
PSA2452	10	00	28	06
Mean*	12.2	1.0	22	3.0
STDEV	2.17	2.24	6.60	3.0

10

15

\* The efficacy of the catheter coated with M-EDTA was significantly higher than the Arrow Gard (p = 0.009)

-50-

*X. Maltophilia (XMAL) Strains*

Table 17 demonstrates the efficacy of the M-EDTA catheters against *X. maltophilia* strains.

5

TABLE 17 - ZONES OF INHIBITION - DIAMETER (mm)

Strain No.	M/EDTA	TMP/SMX	CFTZ	ARROW GARD
XMAL5653	24	37	32	12
XMAL2496	34	22	29	00
XMAL8929	37	40	20	00
XMAL2657	35	30	15	04
XMAL2172	15	15	20	00
Mean*	29	28.8	23.3	3.0
STDEV	9.3	10.38	7.05	5.22

10

15

\* The efficacy of the catheter coated with M-EDTA was significantly higher than the Arrow Gard (p = 0.0016)

20

The foregoing results demonstrate that M-EDTA coated catheters have a broad spectrum activity against various microbial agents that can cause CVC related infections. This activity in the M-EDTA coated catheters is superior and provides a broader spectrum anti-microbial activity than that provided using Arrow Gard catheters.

25

EXAMPLE 16SHELF LIFE AND STABILITY

30

OF THE COATED M-EDTA (IN SERUM)

Catheters coated with M-EDTA, as well as control and Arrow catheters were tested at baseline (day 1 - D1) against *S. epidermidis* using a zone of inhibition measure for relative anti-microbial activity. Then the same

35

-51-

catheters were placed in serum at 37°C and tested at days 3, 7, 15 and 30 to determine inhibitory efficacy over time. (Table 17). In addition, segments of the same catheters were kept for 30 and 60 days at 25°C then tested to determine anti-microbial activity as a measure of the shelf life of catheters with such coatings (Table 18).

# STABILITY OF M-EDTA COATED CATHETERS

## TABLE 17 - ZONES OF INHIBITION - DIAMETER (mm)

	<u>D1</u>	<u>D3</u>	<u>D7</u>	<u>D15</u>	<u>D30</u>
M-EDTA	31	21	16	14	10
Control	0	0	0	0	0
Arrow Gard	14	07	07	05	03

## TABLE 18 - ZONES OF INHIBITION - DIAMETER (mm)

	<u>DAY 30</u>		<u>DAY 60</u>
	<u>Serum</u> <u>37°C</u>	<u>25°C</u>	<u>25°C</u>
M-EDTA	10	34	32
Control	0	0	0
Arrow Gard	3	13	12

The foregoing studies demonstrate that M-EDTA coated catheters maintain excellent anti-microbial (particularly anti-S epidermidis) efficacy for at least two weeks in serum at 37°C and at least two months at 25°C. Whereas, the efficacy of the Arrow Gard catheters decreases rapidly within three days in serum (37°C).

-52-

EXAMPLE 17  
IN VIVO EFFICACY OF M-EDTA  
COATED CATHETERS IN A RABBIT MODEL

5           Animal studies with polyurethane catheters coated with minocycline plus EDTA are provided. The results are consistent with the extensive *in vitro* data described herein. Currently, the only antibiotic-coated catheters on the market are those produced by Arrow. These  
10 catheters are coated with chlorhexidine gluconate and silver sulfadiazine. They have been described in a clinical study done by Maki et al. as capable of reducing the rate of catheter-related sepsis five fold.

15           An established *in vivo* rabbit model was used in the present example (Sherertz et al. *Journal of Infectious Diseases* 167:98-106, 1993). Catheters were inserted percutaneously in the rabbit under aseptic conditions. Immediately after insertion, the catheter insertion site  
20 was inoculated with 0.1 ml of  $10^5$  colony forming units (CFU) of *Staphylococcus aureus* from the bloodstream of a patient with catheter-related *S. aureus* bacteremia. Seven days after insertion, the catheters were removed and the subcutaneous (SQ) as well as the tip of the  
25 catheters were cultured by quantitative catheter cultures.

**PREPARATION OF M-EDTA COATED CATHETERS**

30           Catheters were first pretreated with a cationic surfactant tridodecylmethylammonium chloride (TDMAC). (Example 11). Other surfactants, such as benzalkonium chloride, may also be used. Treatment of a catheter with a surfactant will enable subsequent bonding of anionic  
35 substances, such as the antibiotic minocycline (mino) and EDTA to the surface. For the present studies,

-53-

polyethylene catheters already coated with TDMAC were immersed in a 60 mg/ml solution of EDTA and 60 mg/ml minocycline, (Bio-Guard AB coating, Cook Critical Care, Bloomington, Ind.). These polyethylene catheters were  
5 manufactured by Cook Critical Care (Bloomington, Ind.), 5.0 Fr (18 ga), 15 cm (5 7/8 in)). For these *in vivo* studies, the catheters were cut into 6 cm segments before treating with the M-EDTA solution.

10           Solution A. 3 vials of minocycline (100 mg each) diluted with 0.8 ml of sterile water for injection, USP to obtain 2.4 ml of 120 mg/ml minocycline;

              Solution B. 1.6 ml of 150 mg/ml EDTA was added to.  
15 0.4 ml sterile water to obtain 2 ml of 120 mg/ml EDTA. Finally, 2 ml of solution A was added to 2 ml solution B, resulting in a 4 ml solution of 60 mg/ml minocycline and 60 mg/ml EDTA.

20           All catheters used were of the polyurethane type made by Arrow or Cook. The following results were obtained in the experiment where catheters were cultured by either the standard semiquantitative roll-plate culture technique (Maki et al., 1977, *N. Engl. J. Med.*, 296:1305-  
25 1309) or the sonication (Sherertz et al., 1990, *J. Clin. Microbiol.*, 28:76-82) technique.

              The data in Tables 19 and 20 demonstrated the consistently inhibitory activity of the M-EDTA coated  
30 catheters against *S. aureus* colonization.

-54-

TABLE 19 - NUMBER OF *S. AUREUS*  
COLONIES CULTURED BY ROLL-PLATE

	<u>Catheter Type</u>	<u>Catheter Tip</u>	<u>Catheter SQ*</u>
	Control	>1000	>1000
5	Control	>1000	>1000
	Arrow Gard <sup>†</sup>	2	10
	Arrow Gard	0	0
	Arrow Gard	8	10
	Arrow Gard	2	8
10	M-EDTA	0	0
	M-EDTA	0	0

† Coated with chlorhexidine gluconate and silver sulfadiazine

\* Subcutaneous catheter segment

15

TABLE 20 - NUMBER OF *S. AUREUS*  
COLONIES CULTURED BY ROLL-PLATE

	<u>Catheter Type</u>	<u>Catheter Tip</u>	<u>Catheter SQ*</u>
	Control	>1000	>1000
20	Control	18	25
	Arrow Gard <sup>†</sup>	>1000	>1000
	Arrow Gard	1	16
	M-EDTA	0	0
25	M-EDTA	0	0

The data in Table 21 was obtained using catheter segments cultured by the quantitative sonication technique (as described by Sheretz et al. (1990)). This data demonstrates again the consistently anti-*S. aureus* colonizing effect provided through coating a catheter or other device with a combination of minocycline and EDTA.

30



-55-

TABLE 21 - NUMBER OF *S. AUREUS*  
COLONIES CULTURED BY SONICATION

<u>Catheter Type</u>	<u>Catheter Tip</u>	<u>Catheter SQ*</u>
Control	40	60
Control	380	>1000
Arrow Gard†	180	>1000
Arrow Gard	0	20
M-EDTA	0	0
M-EDTA	0	0

These studies demonstrate the complete prevention of colonization upon using M-EDTA coated catheters compared to the partial prevention achieved using the Arrow Gard catheters.

#### EXAMPLE 18

##### IN VIVO EFFICACY OF M-EDTA CATHETERS

The present example further demonstrates the anti-microbial activity of the coated M-EDTA devices *in vivo*. The M-EDTA-coated catheters were prepared as described in Example 17.  $10^4$  colony forming units of *S. aureus* were inoculated at the insertion site of a catheter coated with M-EDTA (as described in Example 13), with chlorhexidine gluconate and silver sulfadiazine (the Arrow Gard catheter) or with TDMAC alone with no added antibiotic.

The rabbit model described in Sherertz et al. (1993) was used in the present study, i.e., New Zealand white rabbits between 2-3 months old and weighing 2-3 kg. The data in Table 22 demonstrates the superior anti-staphylococcal and total inhibitory activity of MEDTA as

-56-

compared to the partial anti-*S. aureus* activity achieved with the Arrow Gard catheter.

**TABLE 22- NUMBER OF *S. AUREUS*  
COLONIES CULTURED BY ROLL-PLATE**

5

10

15

20

25

Catheter No.	Catheter Type	Catheter Tip	Catheter SQ	Catheter Site Purulence
1	Control	> 1000	> 1000	Yes
2	Control	> 1000	> 1000	Yes
3	Control	> 1000	> 1000	Yes
4	Control	> 1000	> 1000	Yes
5	Arrow Gard	3	10	No
6	Arrow Gard	15	10	No
7	Arrow Gard	15	15	No
8	Arrow Gard	20	15	No
9	M-EDTA	0	0	No
10	M-EDTA	0	0	No
11	M-EDTA	0	0	No
12	M-EDTA	0	0	No
13	M-EDTA	0	0	No
14	M-EDTA	0	0	No
15	M-EDTA	0	0	No
16	M-EDTA	0	0	No

**EXAMPLE 19 - IN VIVO COMPARATIVE STUDY**  
**OF M-EDTA-COATED CATHETERS V. CHLORHEXIDINE/SILVER**  
**SULFADIAZINE-COATED CATHETERS**

30

For this example, catheters were cultured by a sonication quantitative culture technique described in

-57-

Sheretz et al. (1990). The Sheretz et al. article is specifically incorporated herein by reference for this purpose. The sonication of technique is a quantitative culture technique, and is described in Raad et al. (1992) (Diagn. Microbiol. Infect. Dis., 15:13-20). The M-EDTA catheters were coated as described in Example 11. The chlorhexidine/silver sulfadiazine coated catheters are commercially available from Arrow International, Inc. (300 Bernville Road, Reading, PA 19605) (Arrow Gold catheters). The data in Table 23 again demonstrates the consistently effective anti-microbial, particularly the anti-S. aureus, activity of the M-EDTA coated devices of the invention. As well as the superior anti-microbial activity of the M-EDTA devices as compared to the Arrow Gard catheter.

**TABLE 23 - NUMBER OF *S. AUREUS* COLONIES CULTURED BY SONICATION**

Catheter Type	Catheter Tip	Catheter SO
Control	600	520
Control	400	480
Control	600	N/A
Control	640	N/A
Arrow Gard	40	80
Arrow Gard	120	80
Arrow Gard	0	160
Arrow Gard	80	160
M-EDTA	0	0
M-EDTA	0	0
M-EDTA	0	0
M-EDTA	0	0
M-EDTA	0	0
M-EDTA	0	0
M-EDTA	0	0
M-EDTA	0	0

-58-

EXAMPLE 20 - IN VIVO ANTI-MICROBIAL  
ACTIVITY OF M-EDTA COATED CATHETERS

5 This study was performed in the rabbit model as  
described in Example 18.  $10^4$  colony forming units (CFU)  
of *S. aureus* (a PI strain) were used to infect the  
catheter insertion site. The catheters were cultured by  
sonication. (Sheretz et al. (1990)). The Arrow Gard and  
Cook catheters coated with EDTA (Example 17) were  
10 employed in the study. The control catheters used were  
again the Cook catheters that have a coating of TIDMAC,  
but are without antibiotic or EDTA. Table 24 provides  
the data collected in this study. The results in Table  
24 again demonstrate the *in vivo* effectiveness of the M-  
15 EDTA coated catheters for inhibiting infection by *S.*  
*aureus in vivo*.

Catheters were inserted into the subcutaneous space  
of New Zealand white rabbits 2-3 months old and weighing  
20 2-3 kg. A 0.1 ml of  $10^4$  colonies of a virulent *S. aureus*  
strain (PI strain) was injected at the insertion site.  
The rabbits were sacrificed on day 7. Catheters were  
aseptically removed and the 2 cm tip cultured by the  
sonication technique. The results are shown in Table 24.  
25 These results again demonstrate the *in vivo* effectiveness  
of M-EDTA against *S. aureus* infection. These results  
confirm previous experiments whereby M-EDTA coated  
catheters prevented staphylococcal colonization and  
catheter infection compared to partial prevention by the  
30 Arrow catheters.

-59-

TABLE 24 - NUMBER OF *S. AUREUS*  
COLONIES CULTURED BY SONICATION

	Catheter No.	Catheter Type	Catheter Tip	Catheter Site Purulence
5	1	Control	$> 10^5$	Yes
	2	Control	$> 10^5$	Yes
	3	Control	$> 10^5$	Yes
	4	Control	$> 10^5$	Yes
	5	Arrow Gard	$> 10^3$	No
10	6	Arrow Gard	16	No
	7	Arrow Gard	0	No
	8	Arrow Gard	0	No
	9	Arrow Gard	0	No
	10	Arrow Gard	0	No
15	11	Arrow Gard	0	No
	12	Arrow Gard	0	No
	13	Arrow Gard	0	No
	14	M-EDTA	0	No
	15	M-EDTA	0	No
20	16	M-EDTA	0	No
	17	M-EDTA	0	No
	18	M-EDTA	0	No
	19	M-EDTA	0	No
	20	M-EDTA	0	No
25	21	M-EDTA	0	No
	22	M-EDTA	0	No

-60-

## BIBLIOGRAPHY

The following references are specifically  
incorporated herein by reference for the purposes  
5 indicated:

1. Harper WE and Epis JA (1987), Effect of  
chlorhexidine/EDTA/Tris against bacterial isolates from  
clinical specimens., *Microbios.*, 51:107-112.  
10
2. Said AA et al. (1987), Expression of H1 outer-  
membrane protein of *Pseudomonas aeruginosa* in relation to  
sensitivity to EDTA and polymyxin B., *J. Med. Microbiol.*,  
24:267-274.  
15
3. Root JL et al. (1988), Inhibitory effect of disodium  
EDTA upon the growth of *Staphylococcus epidermidis* in  
vitro: Relation to infection prophylaxis of Hickman  
catheters., *Antimicrob. Agents Chemother.*, 32:1627-1631.  
20
4. Clumeck N et al. (1984), Treatment of severe  
staphylococcal infections with a rifampin-minocycline  
association., *J. Antimicrob. Chemother.*, 13(S):17-22.
- 25 5. Yourassowsky E et al. (1981), Combination of  
minocycline and rifampin against methicillin and  
gentamicin resistant *Staphylococcus aureus*., *J. Clin.*  
*Pathol.*, 34:559-563.
- 30 6. Zinner SH et al. (1981), Antistaphylococcal activity  
of rifampin with other antibiotics., *J. Infect. Dis.*,  
144:365-371.
- 35 7. Segreti J et al. (1989), In vitro activity of  
minocycline and rifampin against staphylococci., *Diagn.*  
*Microbiol. Infect. Dis.*, 12:253-255.

-61-

8. Yuk JH et al. (1991), Minocycline as an alternative antistaphylococcal agent., *Rev. Infect. Dis.*, 13:1023-1024.
- 5 9. Root et al. (1988), Inhibitory Effect of Disodium EDTA upon the Growth of *Staphylococcus epidermidis* In Vitro: Relation to Infection Prophylaxis of Hickman Catheters., *Antimicrobial Agents and Chemotherapy*, 32(11):1627-1631.
- 10 10. Goodman and Gilman's *The Pharmacological Basis of Therapeutics*, 8th edition (1990), Pergamon Press
11. The Merck Index, 11th edition (1989), Merck & Co.,  
15 Inc. Publishers, p. 1621.
12. Machnicka et al. (1986), *Folia Histochem. Cytobiol.*, 24(10):65-70.
- 20 13. Tojo M et al. (1988), Isolation and characterization of a capsular polysaccharide adhesion from *Staphylococcus epidermidis*., *J. Infect. Dis.*, 157:713-722.
14. Khoury AE and Costerton JW (1991), Bacterial  
25 biofilms in nature and disease. In: *Dialogues in Pediatric Urology*, 14:1-8.
15. Nickel JC et al. (1985), Tobramycin Resistance of *Pseudomonas aeruginosa* Cells Growing as a Biofilm on  
30 Urinary Catheter Material., *Antimicrobial Agents and Chemotherapy*, 27:619-624.
16. Evans RC and Holmes CJ (1987), Effect of Vancomycin Hydrochloride on *Staphylococcus epidermidis* Biofilm  
35 Associated with Silicone Elastomer., *Antimicrobial Agents and Chemotherapy*, 31:889-894.

-62-

17. Solomon et al. (1987), *J. Controlled Release*, 6:343-352.
18. U.S. Patent No. 4,442,133.
- 5 19. U.S. Patent No. 4,678,660.
20. U.S. Patent No. 4,749,585.
- 10 21. U.S. Patent No. 4,895,566.
22. U.S. Patent No. 4,917,686.
23. U.S. Patent No. 4,107,121.
- 15 24. U.S. Patent No. 5,013,306.
25. U.S. Patent No. 4,952,419.
- 20 26. Sherertz et al. (1989), *Antimicrob Agents Chemother*, 33:114-118.



-63-

CLAIMS

1. An implantable medical device resistant to microbial  
5 growth and coated with at least one of EDTA or  
minocycline.

2. A catheter resistant to glycocalyx formation, said  
10 catheter being coated with at least one of EDTA or  
minocycline.

3. The implantable device of claim 1 or catheter of  
15 claim 2 coated with EDTA.

4. The medical device of claim 1 or catheter of claim 2  
coated with minocycline.  
20

5. The medical device of claim 1 or catheter of claim 2  
coated with minocycline and EDTA.  
25

6. The medical device of claim 1 or catheter of claim 2  
defined further as prepared by a process of:

obtaining a medical device or catheter; and  
30  
treating the device or catheter surface with a  
preparation including at least one of  
minocycline or EDTA.

35

-64-

7. The medical device or catheter of claim 6 wherein the preparation includes minocycline and EDTA.

5 8. The medical device or catheter of claim 7 wherein the preparation includes between about 10 to about 100 mg/ml minocycline and between about 10 to about 100 mg/ml EDTA.

10

9. The medical device or catheter of claim 8 wherein the preparation includes about 60 mg/ml minocycline and about 60 mg/ml EDTA.

15

10. The medical device or catheter of claim 6 wherein the device or catheter is coated with a surfactant.

20

11. The medical device or catheter of claim 10 wherein the surfactant is tridodecylmethyl ammonium chloride.

25

12. The medical device or catheter of claim 10 wherein the surfactant is benzalkonium chloride.

30

13. The medical device of claim 1 or 6 or catheter of claim 2 or 6 further defined as a central venous catheter, a peripheral intravenous catheter, an arterial catheter, a Swan-Ganz catheter, a hemodialysis catheter, an umbilical catheter, a percutaneous nontunneled silicone catheter, a cuffed tunneled central venous catheter or a subcutaneous central venous port.

35

-65-

14. The medical device of claim 1 or 6 or catheter of claim 2 or 6 further defined as a urinary catheter or a peritoneal catheter.

5

15. A mixture of minocycline and at least about 10 mg/ml EDTA.

10 16. The mixture of claim 15 including between about 10 mg/ml and about 100 mg/ml EDTA.

15 17. The mixture of claim 15 including between about 0.001 mg/ml and 100 mg/ml minocycline.

18. The mixture of claim 17 including about 30 mg/ml EDTA and about 30 mg/ml minocycline.

20

19. The mixture of claim 17 including about 60 mg/ml EDTA and about 60 mg/ml minocycline.

25

20. The mixture of claim 15 including about 3 mg/ml minocycline and about 30 mg/ml EDTA in a saline carrier solution.

30

21. An EDTA solution for use in inhibiting polysaccharide glycocalyx formation comprising a solution containing at least about 10 mg/ml EDTA.

35

-66-

22. The EDTA solution of claim 21 including about 30 mg/ml EDTA.

5 23. A minocycline solution for use in preventing catheter infection containing between about 0.001 to about 100 mg/ml minocycline.

10 24. The minocycline solution of claim 23 including about 3 mg/ml minocycline.

15 25. An EDTA and minocycline solution for use in preventing catheter infection and polysaccharide glycolyx formation including between about 0.001 and 100 mg/ml minocycline and between about 10 and 100 mg/ml EDTA.

20 26. The EDTA and minocycline solution of claim 25 including about 30 mg/ml EDTA and about 3 mg/ml minocycline.

25 27. A method of preparing a glycolyx-resistant medical device or catheter comprising coating the device or catheter with the mixture of claim 19 and allowing the coating to dry on the surface of the device or catheter.

30

28. The method of claim 27 wherein the device or catheter is an indwelling catheter.

35

-67-

29. The method of claim 27 wherein the device or catheter is resistant to formation of polysaccharide-rich glycocalyx.

5

30. The method of claim 29 wherein the device or catheter is resistant to formation of a staphylococcal glycocalyx.

10

31. The method of claim 27 wherein the device or catheter is a central venous catheter or a triple lumen catheter.

15

32. A method for preparing a biofilm-resistant medical device using a pharmaceutical preparation of minocycline and EDTA, comprising:

obtaining a medical device;

20

preparing preparation including at least about 10 mg/ml minocycline and at least about 10 mg/ml EDTA; and

25

treating the device surface with the pharmaceutical preparation to allow the formation of a film of the preparation on the device surface.

30

33. The method of claim 32 wherein the medical device is a catheter.

34. The method of claim 32 wherein the biofilm is a microbial glycocalyx.

35

-68-

35. The method of claim 32 wherein the biofilm is a polysaccharide-rich glycocalyx.

5 36. The method of claim 32 wherein the biofilm is a staphylococcal glycocalyx.

10 37. The method of claim 32 wherein the pharmaceutical preparation includes between about 10 to about 100 mg/ml minocycline and between about 10 to about 100 mg/ml EDTA.

15 38. The method of claim 32 wherein the pharmaceutical preparation includes about 60 mg/ml minocycline and about 60 mg/ml EDTA.

20 39. A method for inhibiting polysaccharide glycocalyx formation on a catheter comprising flushing the catheter periodically with a preparation including at least about 10 mg/ml EDTA in a pharmacologically acceptable carrier solution.

25 40. The method of claim 39 wherein the preparation includes about 10 mg/ml and about 100 mg/ml EDTA.

30 41. The method of claim 39 wherein the preparation includes minocycline.

35 42. The method of claim 39 wherein the preparation includes between about 0.001 mg/ml and about 100 mg/ml minocycline.

-69-

43. The method of claim 39 wherein the preparation includes about 30 mg/ml EDTA and about 3 mg/ml minocycline.

5

44. The method of claim 39 wherein the catheter is a tunneled catheter or an untunneled catheter.

10 45. The method of claim 39 wherein the catheter is to be flushed once every 4-24 hours.

15 46. A method for eliminating microbial glycoalkyx formation at a catheter comprising:

preparing a solution of minocycline and EDTA in a carrier solution to provide an M-EDTA preparation; and

20

flushing the catheter periodically with the M-EDTA preparation.

25 47. The method of claim 46 wherein the solution includes about 0.001-100 mg/ml minocycline and about 10-100 mg/ml EDTA.

30 48. The method of claim 46 wherein the solution includes about 3 mg/ml minocycline and about 30 mg/ml EDTA.

35 49. The method of claim 46 wherein the microbial glycoalkyx is a Staphylococcal glycoalkyx.


-70-

50. The method of claim 45 wherein the Staphylococcal glycocalyx is an *S. epidermidis* glycocalyx or an *S. aureus* glycocalyx.

5

51. The method of claim 46 wherein the catheter is flushed once every about 24 hours with between about 1-10 ml of the solution of claim 48.






**FIG. 1**

**SUBSTITUTE SHEET**


2/11



**FIG. 2**

**SUBSTITUTE SHEET**


3/11



*FIG. 3*


**SUBSTITUTE SHEET**

4/11



**FIG. 4**


**SUBSTITUTE SHEET**



**FIG. 5**

**SUBSTITUTE SHEET**


6/11



**FIG. 6**

**SUBSTITUTE SHEET**


7/11



**FIG. 7**

**SUBSTITUTE SHEET**






**FIG. 8**

SUBSTITUTE SHEET




9/11



**FIG. 9**

**SUBSTITUTE SHEET**

10/11



**FIG. 10**

**SUBSTITUTE SHEET**

11/11




FIG. 11A




FIG. 11B

SUBSTITUTE SHEET

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US93/10893**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(5) : A01N 25/02, 25/08; A61F 2/04; A61M 25/01

US CL : 424/405, 409, 423; 604/53

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/405, 409, 423; 604/53

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,Y	US, A, 5,202,449 (HASEGAWA ET AL.) 13 APRIL 1993, column 5, lines 10-13, 29-31.	21-26

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be part of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z* document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means	
*P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

20 DECEMBER 1993

Date of mailing of the international search report

16 FEB 1994

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Authorized officer

CARLOS AZPURU

Facsimile No. NOT APPLICABLE

Telephone No. (703) 308-2351

Form PCT/ISA/210 (second sheet)(July 1992)\*

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US93/10893

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☒ Claims Nos.: 13, 14, and 51  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

